文献速递脊柱关节炎

粪便钙卫蛋白升高与中轴型脊柱关节炎疾病状态更差相关:SPARTAKUS队列结果

Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该研究比较了中轴型脊柱关节炎(axSpA)患者与健康对照的粪便钙卫蛋白(F-calprotectin)和抗酿酒酵母抗体(ASCA)水平,并分析其与疾病亚型及当前状态的关系。结果显示,F-calprotectin升高在axSpA患者中更常见,且与更差的疾病活动度和身体功能评分相关;ASCA血清阳性率在axSpA亚型间相似,但与临床结局无关。

要点

  • F-calprotectin升高(≥50 mg/kg)见于27%的nr-axSpA、38%的AS和6%的对照。
  • AS患者F-calprotectin几何均值高于nr-axSpA(41 vs 24 mg/kg,P=0.037)。
  • F-calprotectin升高与更差的ASDAS-CRP、BASFI和患者总体VAS相关。

核心结论

  • 在axSpA患者中,以F-calprotectin升高为标志的肠道炎症与更差的疾病活动度和身体功能相关,可能是更严重疾病的标志。

研究设计与样本

  • 研究比较了连续临床诊断为axSpA的患者(nr-axSpA n=40,AS n=90)与健康对照(n=35)的F-calprotectin和血清ASCA水平。

主要发现

  • F-calprotectin升高(≥50 mg/kg)在nr-axSpA中占27%,AS中占38%,对照组中占6%。
  • AS患者F-calprotectin几何均值显著高于nr-axSpA(41 vs 24 mg/kg,P=0.037),且各axSpA亚型均显著高于对照组。
  • F-calprotectin升高的axSpA患者在患者总体VAS、ASDAS-CRP和BASFI上显著差于F-calprotectin正常者(校正年龄、性别、NSAID使用、抗风湿治疗和CRP)。
  • ASCA滴度和血清阳性率(≥10 U/ml)在nr-axSpA(IgA/IgG阳性率8%/26%)和AS(7%/28%)间相似,且与临床结局无关。
  • 与对照组(IgA/IgG阳性率0%/17%)相比,ASCA IgA在两个axSpA亚型中均显著更高,IgG在AS组显著更高。

关键数值与推荐

  • F-calprotectin升高定义为≥50 mg/kg。
  • ASCA血清阳性定义为≥10 U/ml。

临床怎么用

  • 对于axSpA患者,可考虑检测F-calprotectin以识别可能具有更差疾病活动度和身体功能的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine faecal calprotectin (F-calprotectin) levels and presence of anti-Saccharomyces cerevisiae antibodies (ASCA) and their associations with disease subtype and current status in axial SpA (axSpA). METHODS: F-calprotectin and ASCA in serum were compared between consecutive patients with a clinical axSpA diagnosis, classified as non-radiographic axSpA (nr-axSpA; n = 40) or AS (n = 90), and with healthy controls (n = 35). Furthermore, standard axSpA outcome measures were compared between axSpA patients (nr-axSpA and AS combined) with elevated vs normal F-calprotectin, ASCA IgA and IgG, respectively. RESULTS: Elevated F-calprotectin (⩾50 mg/kg) was observed in 27% of nr-axSpA patients, 38% of AS patients and 6% of controls. F-calprotectin was significantly higher in AS vs nr-axSpA [AS: geometric mean 41 (95% CI 32, 54) mg/kg; nr-axSpA: 24 (95% CI 16, 38) mg/kg; P = 0.037], and in each axSpA subtype vs controls. Overall, worse disease activity and physical function scores were observed among axSpA patients with elevated vs normal F-calprotectin levels, with significant differences regarding patient's visual analogue scale for global health, ASDAS using CRP, and BASFI (adjusted for age, sex, NSAID use, anti-rheumatic treatments, and CRP). ASCA titres and seropositivity (⩾10 U/ml) were similar in nr-axSpA (IgA/IgG-seropositivity: 8%/26%) and AS (7%/28%), and clinical outcome measures did not differ between patients with elevated vs normal ASCA IgA or IgG, respectively. Compared with controls (IgA/IgG-seropositivity: 0%/17%), ASCA IgA was significantly higher in both axSpA subtypes, and IgG was significantly higher in the AS group. CONCLUSION: In patients with axSpA, gut inflammation measured by elevated F-calprotectin is associated with worse disease activity and physical function, and may be a marker of more severe disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Olofsson T, Lindqvist E, Mogard E, et al. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort. Rheumatology (Oxford). 2019. PMID: 30649509. doi:10.1093/rheumatology/key427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。